New psychotropics: Quetiapine, an antipsychotic agent;Nova psychofarmaka: Antipsychotikum quetiapin

Psychiatrie

Volumn 4, Issue 2, 2000, Pages 120-133

  Svestka, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Atypical antipsychotics; Overview; Quetiapine

Indexed keywords

CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; LIOTHYRONINE; METOCLOPRAMIDE; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PLACEBO; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; THYROXINE; TIOTIXENE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; ZIPRASIDONE;

AKATHISIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; THYROID HORMONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO; WEIGHT GAIN;

EID: 0033693168     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbations of schizophrenia: A comparison with haloperidol and placebo
2. Extrapyramidal symptoms and tolerability profile of Seroquel (quetiapine). An overview of phase II/III placebo controlled trials
3. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine
4. Antipsychotic drug affinities at alpha-2 adrenoceptor subtypes in post-mortem human brain
5. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
6. Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats
7. Clozapine-like behavioral effects of Seroquel (ICI 204,636) in squirrel monkeys
8. A multicenter, double-blind, randomized comparison of quetiapine (ICI 204,636) and haloperidol in schizophrenia
9. Activity of Seroquel (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine
10. Efficacy and tolerability of Seroquel compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment
11. ICI 204,636, a novel atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia
12. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
13. ICI 204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia
14. QT interval prolongation associated with quetiapine (Seroquel) overdose
15. D2 and 5-HT2A receptor binding of different doses of quetiapine in schizophrenics, a PET study
16. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentration after discontinuation of quetiapine (Seroquel) in patients with schizophrenia
17. Tardive dyskinesia with quetiapine
18. Seroquel: Electrophysiological profile of a potential atypic antipsychotic
19. Seroquel: New pre-clinical research data confirm atypical antipsychotic actions
20. Pharmacology of Seroquel (ICI 204,636): An atypical dibenzothiazepine antipsychotic
21. Quetiapine fumarate (Seroquel): A new atypical antipsychotic
22. Quetiapine, an atypical antipsychotic
23. Focus on quetiapine
24. In vitro prediction of potential metabolic drug interactions for Seroquel
25. Quetiapine. A review of its use in schizophrenia
26. N-[11C]methyl-spiperone PET, in contrast of [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic
27. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636)
28. Loss of consciousness from acute quetiapine overdosage
29. Patient satisfaction and acceptability of long-term treatment with quetiapine
30. Adding Seroquel to lithium does not increase extrapyramidal effects
31. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment Of schizophrenia
32. IBZM-SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol
33. 1998 Annual Report of the American Association of Poison Control Centers Toxic Expousure Surveillance System
34. Quetiapine (Seroquel): An effective and well-tolerated atypical antipsychotic
35. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug
36. Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine 2A-receptor blockade
37. Quetiapine and risperidone in outpatients with psychotic disorders: Results of the QUEST trial
38. Agonist and antagonist actions of antipsychotics agent at 5-HT1A receptors: A (35S) GTR gammas binding study
39. Safety in overdose of quetiapine: A case report
40. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
41. Sexual dysfunction: The unspoken side effect of antipsychotic
42. Pharmacokinetics and safety of lithium co-administered with Seroquel (quetiapine)
43. Drug metabolism and atypical antipsychotics
44. Effect of clozapine-quetiapine combination therapy on weight and glycemic control. Preliminary findings
45. Receptor mechanisms of antipsychotic drug atypicality
46. Seroquel: Biochemical profile of a potential atypical antipsychotic
47. Quetiapine in the treatment of hallucinations in advanced Parkinson's disease
48. Attentional improvement following quetiapine fumarate treatment in schizophrenia
49. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors
50. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
51. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
52. Quetiapine in patients with schizophrenia a high and low-dose double-blind comparison with placebo
53. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
54. Striatal and extra-striatal D2/D3 receptor blockade for the antipsychotic quetiapine
55. Seroquel and cognitive improvement in patients with schizophrenia
56. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine
57. Efficacy of seroquel (quetiapine) in Parkinson's patients with psychosis
58. Clinical improvement and tolerability is maintained long-term in elderly patients with psychotic disorders treated with quetiapine
59. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic Seroquel (quetiapine fumarate)
60. Multipledose pharmacokinetics of ICI 204,636 in elderly patients with selected psychotic disorders
61. Contrasting effects of chronic clozapine, Seroquel (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain
62. Seroquel (ICI 204,636), a putative atypical antipsychotic, in schizophrenia with positive symptomatology: Results of an open clinical trial and changes of neuroendocrinological and EEG parameters
63. Multiple-dose pharmacokinetics and dose proportionality study of seroquel (ICI 204,636) in male schizophrenic patients
64. Multiple-dose pharmacokinetics of seroquel (quetiapine) in elderly psychotic patients
65. Pharmacokinetics of seroquel (quetiapine) in hepatic and renal insufficiency
66. Effects of haloperidol, risperidone and thioridazine on the pharmacokinetics of quetiapine
67. The effect of phenytoin and cimetidine on the pharmacokinetics of Seroquel
68. High dose elimination pharmacokinetics of quetiapine following overdose